Correlates of protection to influenza virus, where do we go from here? - Wikidata - wikimedia - TriplyDB

Correlates of protection to influenza virus, where do we go from here?

Correlates of protection to influenza virus, where do we go from here?

http://www.wikidata.org/entity/Q37384775

about

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines Cell culture-based influenza vaccines: A necessary and indispensable investment for the future Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice Model-based reconstruction of an epidemic using multiple datasets: understanding influenza A/H1N1 pandemic dynamics in Israel.Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Association between antibody titers and protection against influenza virus infection within households Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children.Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.Advances and challenges in the development and production of effective plant-based influenza vaccines.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 years of age and older.Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial.Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.Positive Contribution of Adjuvanted Influenza Vaccines to the Resolution of Bacterial Superinfections.Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.A modified dose-response model that describes the relationship between haemagglutination inhibition titre and protection against influenza infection.Influenza vaccines: Evaluation of the safety profile.Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults."Gnothi Seauton": Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy.Population Serologic Immunity to human and avian H2N2 viruses in the United States and Hong Kong for Pandemic Risk Assessment.Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View Augmented CD4 T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years Current progress with serological assays for exotic emerging/re-emerging viruses What can imaging tell us about influenza virus transmission and protection?The application of pseudotypes to influenza pandemic preparedness

P2860

Q26783844-C800FE19-6995-425D-9151-22759C6E5B1C Q28084739-A824A9D1-2A52-4403-AE8F-0128F9DCE1B4 Q30201987-F2FD203D-6797-4564-BD5D-91C5EC314E1D Q30205195-133C31A5-A290-4404-91AE-2D60962246D0 Q30210342-EA65F506-A788-4F1E-8F52-F14FA05ADE7F Q30355516-87ED3BCA-CAAE-41D5-AB9C-D21762AF3C15 Q30386196-AB86B5F0-90D2-4514-ADC0-B1D62198E7F6 Q30386260-7817B1EB-F04C-400F-9869-2467970A9632 Q30392895-8F154365-56C7-4FEF-ABAB-DA6E41DAA688 Q34106198-A705C5CA-96E4-488F-ACCF-8F0533280B94 Q35886464-0A7A1E82-5E2E-48C6-B3CB-AF8C35C20BA8 Q36306922-1ECF1DD7-C2BB-4EFA-BA7A-B9B5A297C295 Q37123064-5CC73301-30DB-4083-B5E0-B45119EDB076 Q37130739-A49DEDB3-67FA-4E33-8188-1AAF80422C8F Q37187530-852C6795-E969-46F5-8C56-2C6292D699CA Q37530383-D7CC58B1-4A49-46C3-B1C9-B84DC10A39E7 Q38285425-EDFA88B0-902D-43F3-9D38-45BFD143B88F Q40116011-A75DB487-65F9-4AE9-BE07-2449FB94FC56 Q40138220-76087BB4-A753-4D20-AF5B-891B4C6DAD1C Q40172220-9C927567-8AE2-4B54-8C78-EEB66097496C Q40334782-0E179379-2A77-4568-AD56-4EE3B74044C2 Q40779990-56055B36-08BB-4403-B89F-AFEAD1629C0B Q41027323-1AC798C2-A9A6-44E9-AD9F-EC847309982F Q41993335-FC62026D-5120-4ADE-94DF-733CC9F46E33 Q47105782-31550593-EBC4-4A9B-A42C-B889DEBA827C Q47137425-B31D25E4-A9C8-4CD3-9983-DB157BEC46F0 Q47553316-A822F779-F695-4E5D-9391-BC153BA5050C Q47588018-C13B6B59-704E-4925-97C2-80898316E433 Q49345779-B65DA973-EE23-43C2-996D-7031DD16B823 Q50420352-F65B1F4B-D5C1-4DF0-91C5-6FABE3B69A2C Q52381548-7B80541A-6F18-4014-8896-061B6F261A62 Q54211362-AF8646BD-F699-4B0B-BEB2-21C7AA3B29FB Q55260817-4EA04CBE-ECC7-4E52-AF78-A98382304453 Q56536297-C26D4616-CE80-4E41-8F1C-B6B4947B6798 Q57093922-F1D0E9B9-476B-4C37-BF60-5C4113478C9B Q57275156-A7674928-DEB0-4C1F-B49B-6D0CDAF2B384 Q57575797-6FEDA48B-C65E-4270-B180-044C2E4C7BD0 Q58382401-44CBA93A-AA7E-42B6-822E-9B843F51E0C0

P2860

Correlates of protection to influenza virus, where do we go from here?

http://www.wikidata.org/entity/Q37384775

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Correlates of protection to influenza virus, where do we go from here?

@en

Correlates of protection to influenza virus, where do we go from here?

@nl

type

label

Correlates of protection to influenza virus, where do we go from here?

@en

Correlates of protection to influenza virus, where do we go from here?

@nl

prefLabel

Correlates of protection to influenza virus, where do we go from here?

@en

Correlates of protection to influenza virus, where do we go from here?

@nl

P1433

Q37384775-DEEF0A02-CAEB-49E7-8888-E13ADDB77CDB

P1476

Q37384775-4D424BEE-A581-4763-B582-9A51E6C0DF12

P2093

Q37384775-D14173D2-AE2D-4546-9F22-AFA56302A84D

P2860

Q37384775-0805DA1B-2DC0-4B13-90F3-8FAA4952430C

Q37384775-0C254EAC-0442-4B53-94BF-5F5759E6C3F9

Q37384775-1D6BDEA0-02A8-4B9E-904C-F3666DDA6CDF

Q37384775-2419C0B4-958E-4C6D-B791-48CFB42DC15D

Q37384775-2EB799F4-14FB-497F-9003-0BD9316C509F

Q37384775-37E50AFF-196F-4D33-8E79-081D4E10F77D

Q37384775-39C5874A-255B-4408-AF2E-5EEA5433F84F

Q37384775-3A4255B8-8874-4BCC-8FEB-7296047ED7ED

Q37384775-424FF62F-4C6C-42BA-8DA8-43F0FE35076C

Q37384775-4A6AB85C-277E-45C6-B173-64834519F879

P304

Q37384775-C84A782A-485B-4E50-8A6E-91FD2FE5A0CC

P31

Q37384775-97C6D1E9-18C9-4BDD-A7ED-283010E81B15

P356

Q37384775-D82DEC9B-0A4B-4B20-9AC9-05968B033740

P433

Q37384775-9632891F-7F51-48E8-9F33-6F25AD05F167

P478

Q37384775-5F30C640-DDAD-42AC-86DB-D671B047D897

P50

Q37384775-83D3BD64-124A-46B4-BF92-BBE238F619A7

P577

Q37384775-910B2F91-82E2-44F6-A460-1B1C7FA7E64A

P5875

Q37384775-DCF5A47D-848D-475A-B9F6-2C20535D0FA4

P698

Q37384775-BD8EA9F4-1893-46A2-80E9-BBB6D2FC85C1

P932

Q37384775-A40CAFB2-7DA4-41D8-8D51-1B01B75CF283

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Correlates of protection to influenza virus, where do we go from here?

@en

P2093

Rebecca J Cox

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach.

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

Reproducibility of serologic assays for influenza virus A (H5N1).

P304

405-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.22908

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234069634

http://www.w3.org/2001/XMLSchema#string

P698

23291930

http://www.w3.org/2001/XMLSchema#string

P932

3859764

http://www.w3.org/2001/XMLSchema#string